We showed that SREBP-1 expression was closely related to the prognosis of HCC patients treated by RFA, and that use of small-molecule inhibitors of SREBP-1 could also inhibit metabolism-related EMT. The gene discussed is SREBF1; the disease is hepatocellular carcinoma.